Manila Times Business
Lyell Immunopharma Presents Updated Safety Data and Translational Insights for Rondecabtagene Autoleucel (Ronde-Cel) in Patients with Large B-Cell Lymphoma at European Hematology Association 2026 Congress
More than 100 patients treated with ronde-cel in 2L and 3L+ LBCL, with a manufacturing success rate of 97%No Grade ≥ 3 CRS and low rates of Grade ≥ 3 ICANS, supporting outpatient administrationTranslational data support biological basis for durable responses, including enhanced memory potential of cytotoxic effector cells from CD62L+ enrichment, and CD19/CD20 dual-targeting to overcome low antigen expressionPiNACLE pivotal clinical trial in 3L+ setting data update expected in second half of 2026
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
What Is XM Partner Code Y8MH4 and Why Is It Growing?
2h ago
Eight Saints Launches Firm Intentions, a Clean Anti-Aging Neck Cream, Targeting Skincare's Most Overlooked Area
2h ago
Limitless Sky Launches empty-legs-flights.com - The World’s Most Comprehensive Real-Time Empty Leg Private Jet Platform
2h ago
CSL Delivers World’s First Battery-Powered Self-Unloading Bulk Carrier to Support Adbri Operations
2h ago